Intra-Cellular Therapies (ITCI) Tops Q1 EPS by 16c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Intra-Cellular Therapies (ITCI) PT Lowered to $96 at RBC Capital
May 7, 2024 12:44 PM EDTRBC Capital analyst Brian Abrahams lowered the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $96.00 (from $100.00) while maintaining a Outperform rating.
The analyst comments "This morning ITCI reported 1Q24 earnings and we had a chance to catch up with mgmt to... More
JPMorgan on Intra-Cellular Therapies (ITCI): 'We continue to like ITCI stock'
May 7, 2024 12:32 PM EDTJPMorgan analyst Jessica Fye reiterated an Overweight rating and $75.00 price target on Intra-Cellular Therapies (NASDAQ: ITCI)
The analyst comments "We continue to like ITCI stock on the back of solid 1Q results and with shares having come off of their post-data highs. ITCI reported 1Q24 revenue of $145mm,... More
Jefferies Positive on Intra-Cellular Therapies (ITCI): 'We like the setup ahead of the second MDD readout in late-Q2'
May 7, 2024 8:00 AM EDTJefferies analyst Andrew Tsai reiterated a Buy rating and $105.00 price target on Intra-Cellular Therapies (NASDAQ: ITCI).
The analyst comments "ITCI previously preannounced a Q1 beat (Caplyta sales were $145M vs cons $141M), and mgmt just reiterated its 2024 guidance of $645-675M. Quarterly... More
